Tobias Bittner

MedicineBiochemistry, Genetics and Molecular BiologyNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial”.

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

The Lancet Neurology(2025)10.1016/s1474-4422(25)00024-9

N/A

1.2DataRank · unranked

41 citations

Yan Li, Eric McDade, Jorge J. Llibre‐Guerra, David B. Clifford, Alireza Atri +62 more

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease

JAMA Neurology(2024)10.1001/jamaneurol.2024.0991

N/A

1.0DataRank · unranked

29 citations

Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner, Marzia A. Scelsi +94 more

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial

medRxiv(2024)10.1101/2024.10.29.24316289

N/A

0.351DataRank · unranked

6 citations

Yan Li, Eric McDade, Jorge J. Llibre‐Guerra, David B. Clifford, Alireza Atri +63 more

Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts

Alzheimer's & Dementia(2026)10.1002/alz.71009

N/A

0.269DataRank · unranked

5 citations

Alina Bauer, Christina Rabe, Niels Borlinghaus, Alexander Jethwa, Gwendlyn Kollmorgen +7 more

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

Alzheimer s & Dementia(2024)10.1002/alz.13735

N/A

0DataRank · unranked

13 citations

Yan Li, Johannes Levin, Tammie L.S. Benzinger, Brian A. Gordon, Jason Hassenstab +20 more

Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term

Neurology(2024)10.1212/wnl.0000000000210225

N/A

0DataRank · unranked

13 citations

Corinne Pettigrew, Jiangxia Wang, Marilyn Albert, Kaj Blennow, Tobias Bittner +2 more

Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring(2025)10.1002/dad2.70081

N/A

0DataRank · unranked

4 citations

Anja Soldan, Jiangxia Wang, Timothy J. Hohman, Logan Dumitrescu, Marilyn Albert +5 more

The global Alzheimer's Association round robin study on plasma amyloid β methods

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring(2021)10.1002/dad2.12242

N/A

0DataRank · unranked

45 citations

Leslie M. Shaw, Magdalena Korecka, Teresa Waligórska, Charlotte E. Teunissen, Erik Stoops +30 more